Ultragenyx Pharmaceutical Inc. said early Monday that it has proposed to buy all outstanding common stock of Dimension Therapeutics Inc. for $5.50 per share, or about $138 million. The offer would be offered in cash at close to be effectuated via a tender offer, Ultragenyx said. Dimension Therapeutics shares, which were valued at $4.20 as of Friday’s close, were halted in premarket trade Monday. REGENXBIO Inc. said in late August that it planned to buy Dimension Therapeutics for about $3.41 per share, and that the board of directors of both companies had signed on. But Ultragenyx said that its offer represents “premiums of 24% and 48% over the implied value of the all-stock consideration” offered by REGENXBIO. “As such, the proposal would provide Dimension stockholders with an immediate and certain return on their investment in Dimension and constitutes a superior alternative to the REGENXBIO transaction,” Ultragenyx said. Dimension Therapeutics shares have surged 236% over the last three months, compared with a 2.8% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News